Company Name or Ticker Symbol
Search for other Categories
Celgene Corp  (CELG)
Other Ticker:  
    Sector  Healthcare    Industry Major Pharmaceutical Preparations
Price: $137.7400 $1.43 1.049%
Day's High: $ 138.17 Week Perf: 2.13 %
Day's Low: $ 135.72 30 Day Perf: 3.7 %
Volume (M): 3,652 52 Wk High: $ 138.17
Volume (M$): $ 502,971 52 Wk Avg: $ 117.14
Open: 136.23 52 Wk Low: 96.93
  CELG Charts & Quotes
You need to upgrade your Flash Player

 Market Capitalization (Millions $) 111,735
 Shares Outstanding (Millions) 811
 Employees 6,012
 Revenues (TTM) (Millions $) 11,678
 Net Income (TTM) (Millions $) 2,140
 Cash Flow (TTM) (Millions $) 827
 Capital Exp. (TTM) (Millions $) 239
Celgene Corp
We are a multinational integrated biopharmaceutical company, incorporated in 1986 as a Delaware corporation. We are primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases. Over the last several years, total revenues have steadily grown led by sales of THALOMID(R) (thalidomide), our lead product, which is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers. The sales growth of THALOMID(R) has enabled us to make substantial investments in research and development, which has advanced our broad portfolio of drug candidates in our product pipeline, including a pipeline of IMiDs(R) compounds, which are a class of compounds proprietary to us and having certain immunomodulatory and other biologically important properties.


Celgene's Segments
 Segment    62.85 % of total Revenue
 Segment    1.95 % of total Revenue
 Segment    9.94 % of total Revenue
 Segment    6.38 % of total Revenue
 Segment    0.12 % of total Revenue
Total product sales
 Segment    100 % of total Revenue
 Segment    0.75 % of total Revenue
 Segment    11.09 % of total Revenue
azacitidine injection
 Segment    0.92 % of total Revenue
  Company Estimates  
  Revenue Outlook
Celgene announced annual revenue outlook on Nov. 05, 2015

Earnings Outlook
Celgene Corp issued annual earnings guidance on Nov. 05, 2015

Geographic Revenue Dispersion
United States 59.47 %
All Other 11.8 %
Europe 28.73 %

Hexcel Corp

Double Digit EPS Growth, Sales Lower

Despite soft demand in the first quarter, company has managed to raise it's earnings per share, income increased by 18.64 % to $0.70 per share while Sales fell by -3.8 % to $478.80 millions, year on year.

Colgate Palmolive Co

Deterioration in Earnings, Sales Down Slightly

Colgate Palmolive Co announced disappointing results, eps deteriorated by -11.94 % to $0.59 from $0.67 and Sales declined by -0.49 % to $3.83 billions in the second quarter, year on year.

CELG's Valuation Current
Price to Earnings PE Ratio (TTM) 51.89
Price to Earnings PE Ratio (Expected) 64.67
Price to Sales (TTM) 9.57
Price to Sales (Expected) 12.08
Price to Book 14.62
PEG (TTM) 1.84
CELG's Financial Strength Current
Quick Ratio 3.37
Working Capital Ratio 4.42
Leverage Ratio (MRQ) 2.77
Total Debt to Equity 1.87
Interest Coverage (TTM) 6.91
Debt Coverage (TTM) 0.24
Per Share Current
Earnings (TTM) 2.65 $
Revenues (TTM) 14.4 $
Cash Flow (TTM) 1.02 $
Cash 10.92 $
Book Value 9.42 $
Dividend (TTM) 0 $

• View Valuation Comparisons • View Growth Rates Comparisons

You need to upgrade your Flash Player
CELG's Efficiency Current
Revenue per Employee (TTM) 1,942,382
Net Income per Employee (TTM) 355,872
Receivable Turnover Ratio (TTM) 7.37
Inventory Turnover Ratio (TTM) 0.89
Asset Turnover Ratio (TTM) 0.42
CELG's Profitability Ratio Current
Gross Margin 96.18 %
Operating Margin 37.53 %
Net Margin 31.79 %
Net Cash Flow Margin -
Effective Tax Rate (TTM) 13.59 %
Management Effectiveness Current
Return On Assets (TTM) 7.76 %
Return On Investment (TTM) 8.78 %
Return On Equity (TTM) 33.64 %
Dividend Yield -
Payout Ratio (TTM) -
• View Efficiency Comparisons • View Profitability Comparisons • View Management Effectiveness

Customers Net Income fell by CELG's customers Net margin fell to %
-4.31 % 3.68 %
• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers
You need to upgrade your Flash Player

You need to upgrade your Flash Player

You need to upgrade your Flash Player
Major Competitors Stock performance

5 Days Decrease / Increase
JNJ        2.04% 
LLY        0.37% 
ALXN        4.01% 
ABT        3.95% 
MRK   -0.68%    
BMY        0.91% 
• View Complete Report

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com